Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications
Ezh2 Delays Activation of Differentiation Genes During Normal Cerebellar Granule Neuron Development and in Medulloblastoma.
Journal: bioRxiv : the preprint server for biology
Published: November 28, 2024
Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma.
Journal: Nature genetics
Published: June 01, 2022
Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study.
Journal: JCO precision oncology
Published: March 02, 2022
AAV-vector based gene therapy for mitochondrial disease: progress and future perspectives.
Journal: Orphanet journal of rare diseases
Published: December 21, 2021
Retraction Note: Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.
Journal: Nature neuroscience
Published: December 15, 2021
Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion.
Journal: Cold Spring Harbor molecular case studies
Published: May 25, 2021
Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 27, 2021
Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.
Journal: Cancer research
Published: May 22, 2020
Correction: Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
Journal: Oncogene
Published: October 30, 2019
Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma.
Journal: Nature neuroscience
Published: January 23, 2019
Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide.
Journal: Oncogene
Published: November 26, 2018
Last Updated: 09/26/2026